The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.
February 20, 2025 | Clyde Yancy talks to Priya Freaney and Nisha Parikh about the landscape of cardiovascular care for women and how it can be improved, both for patients and women training to be ...
Clyde Yancy, Roxana Mehran, and Howard Herrmann discuss strategies for increasing clinical trial enrollment among women, including targeting disease phenotypes and sex-specific trials. Sponsored by ...
A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the way.
February 20, 2025 | Clyde Yancy, Roxana Mehran, and Howard Herrmann discuss strategies for increasing clinical trial enrollment among women, including targeting disease phenotypes and sex-specific ...
Clyde Yancy talks to Priya Freaney and Nisha Parikh about the landscape of cardiovascular care for women and how it can be ...
If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback